NASDAQ:PRTC PureTech Health (PRTC) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free PRTC Stock Alerts $27.46 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$27.46▼$27.4650-Day Range$24.50▼$30.9152-Week Range$17.08▼$34.00Volume160 shsAverage Volume425 shsMarket Capitalization$741.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get PureTech Health alerts: Email Address Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About PureTech Health Stock (NASDAQ:PRTC)PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Read More PRTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTC Stock News HeadlinesApril 27, 2024 | seekingalpha.comPureTech Health plc (PRTC) Q4 2023 Earnings Call TranscriptApril 25, 2024 | finance.yahoo.comPureTech Announces Annual Results for Year Ended December 31, 2023May 11, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 18, 2024 | businesswire.comPureTech Health: Notice of ResultsApril 16, 2024 | finance.yahoo.comPureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary FibrosisApril 11, 2024 | lse.co.ukUS FDA hands fast track to PureTech head and neck cancer treatmentApril 11, 2024 | markets.businessinsider.comPureTech's LYT-200 Receives FDA Fast Track Designation For Treatment Of Head & Neck CancersApril 11, 2024 | businesswire.comPureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck CancersMay 11, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 9, 2024 | businesswire.comPureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management TransitionsMarch 18, 2024 | businesswire.comBristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 BillionMarch 13, 2024 | finance.yahoo.comPureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid LeukemiaFebruary 28, 2024 | finance.yahoo.comAKLI Mar 2024 3.000 callFebruary 27, 2024 | lse.co.ukPureTech notes positive results from Shionogi's EndeavorRx ADHD trialFebruary 27, 2024 | finance.yahoo.comPureTech to Present at Two Upcoming Investor ConferencesFebruary 27, 2024 | businesswire.comPureTech to Present at Two Upcoming Investor ConferencesFebruary 27, 2024 | finance.yahoo.comPureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in JapanFebruary 27, 2024 | businesswire.comPureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in JapanFebruary 22, 2024 | finance.yahoo.comPureTech Health plc (PRTC)February 15, 2024 | finance.yahoo.comDown -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a TurnaroundFebruary 9, 2024 | fool.co.ukLSE:PRTC (PureTech Health plc)January 23, 2024 | seekingalpha.comPRTC PureTech Health plcDecember 20, 2023 | msn.comPureTech outlook for 2024December 7, 2023 | finance.yahoo.comPureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023November 14, 2023 | msn.comPureTech Phase 2 study for anti-anxiety drug LYT-300 meets primary endpointOctober 11, 2023 | finance.yahoo.comPureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual MeetingOctober 6, 2023 | bizjournals.comAt Women Who Lead in Life Sciences, female leaders got the spotlight [PHOTOS]See More Headlines Receive PRTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/11/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRTC CUSIPN/A CIK1782999 Webwww.puretechhealth.com Phone617-482-2333Fax617-482-3337Employees111Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.76 Quick Ratio6.76 Sales & Book Value Annual Sales$3.33 million Price / Sales222.65 Cash FlowN/A Price / Cash FlowN/A Book Value$16.94 per share Price / Book1.62Miscellaneous Outstanding Shares27,000,000Free Float25,564,000Market Cap$741.42 million OptionableNot Optionable Beta1.21 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Spencer BallSenior Vice President of Human ResourcesMs. Aleksandra Filipovic M.D.Ph.D., Head of OncologyMs. Cheryl Murphy Ph.D.Head of Grants Management & StrategyMs. Anita Terpstra J.D.Ph.D., Senior VP & Head of Intellectual PropertyMr. Dilip KodiraHead of Data ScienceMs. Anne Burkhardt Ph.D.Head of ResearchDr. Julie Krop M.D. (Age 58)Chief Medical Officer Ms. Joy Bauer M.S.RDN, Chief Nutrition OfficerMr. Robert Lyne (Age 41)Chief Portfolio Officer Mr. William Berry CPAControllerMore ExecutivesKey CompetitorsCogent BiosciencesNASDAQ:COGTArcturus TherapeuticsNASDAQ:ARCTSIGA TechnologiesNASDAQ:SIGAAurinia PharmaceuticalsNASDAQ:AUPHDisc MedicineNASDAQ:IRONView All Competitors PRTC Stock Analysis - Frequently Asked Questions How have PRTC shares performed in 2024? PureTech Health's stock was trading at $28.18 at the beginning of the year. Since then, PRTC shares have decreased by 2.6% and is now trading at $27.46. View the best growth stocks for 2024 here. When is PureTech Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our PRTC earnings forecast. How do I buy shares of PureTech Health? Shares of PRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRTC) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityHow Biden has already won 2024Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PureTech Health plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.